Incyte Gains Development and Commercialization Rights to Tafasitamab (Monjuvi®)
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
China’s Center for Drug Evaluation (CDE) has granted approval for InnoCare Pharma to conduct a Phase II clinical trial of orelabrutinib along with tafasitamab + lenalidomide to treat Non-Hodgkin’s lymphoma (NHL).
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China
BOSTON, MA / ACCESSWIRE / November 3, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), today announced that new data on pelabresib, an investigational BET inhibitor, and tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, will be featured in 14 presentations - including four oral sessions - during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana from December 10-13, 2022.
MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), today announced that new data on pelabresib, an investigational BET inhibitor, and tafasitamab, marketed in the U.S. as Monjuvi® and outside the U.S. by Incyte as Minjuvi®, will be featured in 14 presentations – including four oral sessions – during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana from December 10-13, 2022.
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 21, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi® U.S. net product sales for the third quarter of 2022 and provided an update to its financial guidance for 2022.
BOSTON--(BUSINESS WIRE)--MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: MOR; NASDAQ: MOR), today announced data from the ongoing L-MIND study showing that Monjuvi® (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided long-term efficacy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated for at least 2 years, including six patients on treatment for 5 years or more. Additionally, the frequency of adverse events declined after patients transitioned from combination therapy to monotherapy. The data will be presented during a poster session at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022) in Houston, Texas.
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969) announced today that the first patient was dosed in the phase II registrational trial (Registry number: CTR20221519) of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT).
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT) by the Department of Health, the Hong Kong Special Administrative Region, China.